Research Interests and Experience
Member - Ethics Committee - Institute of Pulmocare & Research (IPCR)
Dr Sujoy Khan is interested in many aspects of immunoglobulin therapy, such as why some patients get side effects during IVIG therapy, how IgG glycosylation may contribute to efficacy of IVIG therapy, and whether the effective dose of IVIG is dependent on body weight.
He is keen to explore the various roles of autoantibodies in autoimmune diseases from identification using routinely available laboratory and research techniques and to translate this into therapeutic options.
He continues to retain interest in the genetic insights of primary immunodeficiency diseases (PIDs), particularly common variable immunodeficiency and secondary antibody deficiency disorders and in setting up a database for PIDs in India.
Selected past projects
Proteomics: Glycosylation status of IgG in commercial immunoglobulin preparations
This research was done at Sheffield Hallam University (2009-2010) using MALDI-MS to examine the glycosylation status of IgG in commercial immunoglobulin preparations.
SDS-PAGE of latex skin testing solutions (non-ammoniated Vs ammoniated)
This research was done at Hull Royal Infirmary (2008) to verify whether the ammoniated latex skin prick testing solution had the relevant allergens when compared with the non-ammoniated solution.
Neuroparalysis and oxime efficacy in organophosphate poisoning
This in-vitro oxime reactivation study was performed while Dr.Khan was in undergraduate training (1997-1999) at the Christian Medical College, Vellore, India. We showed that early intervention with oxime treatment had the potential to reverse butyrylcholinesterase activity after acute organophosphorus poisoning.
[Citation: Khan S, Hemalatha R, Jeyaseelan L, Oommen A, Zachariah A. Neuroparalysis and oxime efficacy in organophosphate poisoning: a study of Butyrylcholinesterase. Human & Experimental Toxicology 2001 April; 20(4): 169-74]